News
ZBH
--
0.00%
--
Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2020
PR Newswire · 09/10 21:30
Zimmer Biomet declares $0.24 dividend
Zimmer Biomet (ZBH) declares $0.24/share quarterly dividend, in line with previous.Forward yield 0.69%Payable Oct. 30; for shareholders of record Sept. 30; ex-div Sept. 29.See ZBH Dividend Scorecard, Yield Chart, &
Seekingalpha · 09/10 20:34
Zimmer Biomet to Present at Morgan Stanley Virtual Global Healthcare Conference
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will be presenting at the Morgan Stanley Virtual Global Healthcare Conference on Tuesday, September 15
PR Newswire · 09/08 12:00
The Zacks Analyst Blog Highlights: Medtronic, Abbott Laboratories, Myriad Genetics, Zimmer Biomet and General Electric
The Zacks Analyst Blog Highlights: Medtronic, Abbott Laboratories, Myriad Genetics, Zimmer Biomet and General Electric
Zacks · 09/04 13:23
Market Digest: BAX, ZBH, NFG
Find the latest Zimmer Biomet Holdings, Inc. (ZBH) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance
Argus Research · 09/04 00:00
Analyst Report: Zimmer Biomet Holdings Inc
Find the latest Zimmer Biomet Holdings, Inc. (ZBH) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance
Argus Research · 09/04 00:00
Zimmer (ZBH) Up 7% Since Last Earnings Report: Can It Continue?
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/03 16:31
Zimmer Biomet to Present at Wells Fargo 2020 Virtual Healthcare Conference
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will be presenting at the Wells Fargo 2020 Virtual Healthcare Conference on Wednesday, September 9, 2020
PR Newswire · 09/03 12:00
Stryker Has Looked A Little Mortal Lately, And The Stock Has Suffered
Stryker has continued to beat expectations, but other med-techs have looked more dynamic, and investor enthusiasm seems to have taken a hit. Stryker's core knee business is still quite strong, and Mako placements remain healthy. A shaky hospital capex environment is creating some complications for Stryker, but I'm more concerned about the ongoing weakness in spine and two straight misses in neuro. Stryker will be fine, but this is a stock to monitor if the shares sell off another 15% or so.
Seekingalpha · 09/01 14:28
Needham's medtech look sees continued gains through year-end, names picks
All evidence indicates the medical technology sector hit its trough in April, as each month since has brought sequential improvement - from a springtime hole where elective medical procedures faced
Seekingalpha · 08/31 22:54
Zimmer Biomet Holdings Inc (ZBH): Hedge Funds Are Snapping Up
Insider Monkey · 08/31 18:34
NuVasive's Valuation Prices In An Excessively Bearish Outlook
NuVasive benefited from improving elective procedure volumes, and revenue beat expectations, but growth lagged rivals like Globus and Medtronic. Delays due to system refinements and COVID-19 have pushed Pulse commercialization into 2H'21, and first-in-man testing for the new robotics system into 2022. The Pulse delays hurt, but NuVasive does have some attractive near-term product opportunities (including X360 and Modulus) and Pulse should eventually help drive some incremental share. The market is pricing NuVasive for sub-20% EBITDA margins and low single-digit revenue growth; doing even modestly better should be enough to drive attractive returns.
Seekingalpha · 08/27 12:14
If Zimmer Biomet Has Turned The Corner In Major Joints, More Beat-And-Raises Could Be Coming
Zimmer not only beat the average-sell side estimates by a wide margin, the company posted its first share gains in major joints in about five years.
Seeking Alpha - Article · 08/25 17:42
No other industry has more at stake this election than health care. Here's how pros are playing it
Investors may be overly concerned about the impact of the presidential election on health care stocks, analysts say.
CNBC.com · 08/20 13:25
'Fast Money Halftime Report' Picks From August 12: Ollie;s, Zimmer Biomet And More
On CNBC's "Fast Money Halftime Report," Jenny Harrington suggested that Zimmer Biomet Holdings Inc (NYSE: ZBH) is a buy.
Benzinga · 08/13 18:37
Why Zimmer Biomet's Stock Is Trading Higher Today
Zimmer Biomet Holdings (NYSE: ZBH) shares are trading higher on Wednesday after analysts at several firms raised their price targets on the stock. The company on Tuesday reported second-quarter results.View more earnings on ZBHZimmer Biomet designs, manufactur
Benzinga · 08/05 19:09
Zimmer Biomet Holdings shares are trading higher after analysts at several firms raised their price targets on the stock. The company on Tuesday reported Q2 results.
Benzinga · 08/05 16:41
Morgan Stanley Maintains Overweight on Zimmer Biomet Holdings, Raises Price Target to $150
Morgan Stanley maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Overweight and raises the price target from $140 to $150.
Benzinga · 08/05 15:02
Morgan Stanley Maintains Overweight on Zimmer Biomet Holdings, Raises Price Target to $150
Morgan Stanley maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Overweight and raises the price target from $140 to $150.
Benzinga · 08/05 15:02
Zimmer Biomet Slips 3.7% On 2Q Profit Decline
Zimmer Biomet fell 3.7% after reporting that second-quarter adjusted earnings per share plummeted to $0.05 from $1.93 in the year-ago quarter. Meanwhile, analysts had expected a loss of $0.73 per share.Zimmer's (ZBH) revenues declined over 38% to $1.23 billion
SmarterAnalyst · 08/05 13:21
Webull provides a variety of real-time ZBH stock news. You can receive the latest news about Zimmer Biomet through multiple platforms. This information may help you make smarter investment decisions.
About ZBH
Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company's products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The Company manages its operations through three geographic operating segments: the Americas, consisting principally of the United States and other North, Central and South American markets; EMEA, consisting principally of Europe and the Middle East and African markets, and Asia Pacific, consisting primarily of Japan and other Asian and Pacific markets. The Company's product category segments include Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic (CMF), and Dental.
More